Larvol Delta - Safety-tolerability-and-preliminary-efficacy-of-CPI818-in-the-treatment-of-moderate-to-severe-atopic-dermatitis

soquelitinib (CPI-818) - Corvus Pharma

https://www.chictr.org.cn/showproj.html?proj=288201

Jan 31, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next